Cover Image
市場調查報告書

異位性皮膚炎:開發平台分析

Atopic Dermatitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232797
出版日期 內容資訊 英文 375 Pages
訂單完成後即時交付
價格
Back to Top
異位性皮膚炎:開發平台分析 Atopic Dermatitis - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 375 Pages
簡介

異位性皮膚炎是皮膚變癢的發炎,也有慢性的症狀拖長,伴隨氣喘和花粉症。 症侯有紅色到帶茶色的灰色斑點,發癢,尤其是夜間變得厲害。有小小隆起的疙瘩,抓的話會有體液流出變成瘡痂,肥厚性的鱗狀皮膚,抓的話潰爛變敏感的皮膚等。

本報告提供異位性皮膚炎的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關最新的開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等新聞和發表。

簡介

  • 調查範圍
  • 異位性皮膚炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Abeome Corporation
  • Accolade Pharmaceuticals, LLC
  • AlbireoPharma
  • Almirall, S.A.
  • Amgen Inc.
  • Amorepacific Corporation
  • Anacor Pharmaceuticals, Inc.
  • AnaMar AB
  • AnaptysBio, Inc.
  • AnGes MG, Inc.
  • Aquinox Pharmaceuticals Inc.
  • arGEN-X BV
  • Blueberry Therapeutics Ltd
  • Brickell Biotech, Inc.
  • Celgene Corporation
  • ChemoCentryx, Inc.
  • ChironWells GmbH
  • 中外製藥
  • Creabilis SA
  • Delenex Therapeutics AG
  • Dermira Inc.
  • Dr. August Wolff GmbH & Co. KG Arzneimittle
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Foamix Pharmaceuticals Ltd.
  • Fountain Biopharma Inc.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Grupo Ferrer Internacional, S.A.
  • Han Wha Pharma Co., Ltd.
  • HanAll Biopharma Co., Ltd.
  • Herantis Pharma Plc
  • Immune Pharmaceuticals Inc.
  • Inflamalps SA
  • 日本煙草產業
  • Johnson & Johnson
  • Kineta, Inc.
  • LegoChem Biosciences, Inc
  • LEO Pharma A/S
  • Madam Therapeutics B.V.
  • MedImmune, LLC
  • NeoPharm Co., Ltd.
  • Novan, Inc.
  • Novartis AG
  • Orbis Biosciences, Inc.
  • 大塚集團
  • Oxagen Limited
  • Pfizer Inc.
  • Pharis Biotec GmbH
  • Pharmedartis GmbH
  • Provectus Biopharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Signum Dermalogix, Inc
  • Spherium Biomed S.L.
  • sterna biologicals Gmbh & Co KG
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd.
  • SWITCH Biotech LLC
  • 武田藥品工業
  • Thesan Pharmaceuticals, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Vicore Pharma AB
  • Vitae Pharmaceuticals, Inc.
  • VivaCell Biotechnology Espana S.L.
  • Xencor, Inc.
  • Ziarco Pharma Ltd

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • A-3914
  • A-5425
  • AKP-11
  • ALX-101
  • AM-1030
  • AN-4161
  • ANB-020
  • apremilast
  • 異位性皮膚炎用Galectin-3抑制適體
  • AQX-1125
  • ARGX-112
  • ARN-077
  • baricitinib
  • BB-2702
  • BBI-2000
  • BBI-5000
  • bertilimumab
  • 異位性皮膚炎、皮膚炎用生技藥品
  • C-21
  • CBP-174
  • CBP-201
  • CCX-6239
  • CDE-001
  • Cis-Urocanic Acid
  • CNTO-7160
  • kobamamido
  • crisaborole
  • CT-101
  • CT-1x1
  • CT-1x2
  • CT-1x3
  • CT-327
  • CT-340
  • Cyclosporine
  • dalazatide
  • DMT-210
  • DRM-02
  • 異位性皮膚炎治療藥
  • 異位性皮膚炎用 TNFR-1拮抗劑
  • deyupirumabu
  • FB-825
  • fevipiprant
  • FIB-116
  • Furestem-AD
  • GBR-830
  • Histimex
  • HS-378
  • JTE-052
  • KPI-150
  • LCB-030110
  • lebrikizumab
  • LEKTI-6
  • LEO-32731
  • LEO-39652
  • mepolizumab
  • MLR-1130
  • mometasone furoate
  • 氣喘、線維症、異位性皮膚炎用 IL-25抑制單株抗體
  • 異位性皮膚炎用 IL-4/IL-13抑制單株抗體
  • 發炎性用腸道疾病、 異位性皮膚炎、大腸癌 Th22細胞/IL-22途徑標的單株抗體
  • N-oleoylethanolamine
  • nemolizumab
  • NPH-12
  • OC-000459
  • OC-2417
  • octenidine hydrochloride
  • OLX-103
  • omiganan pentahydrochloride
  • OPA-15406
  • P-10
  • PAC-14028
  • PDI-192
  • 異位性皮膚炎用 CX3CR1拮抗肽
  • 異位性皮膚炎用 TNFR-1拮抗肽
  • PH-10
  • PL-601
  • PMA-101R
  • PMA-201
  • PMA-411R
  • prednisone
  • PZ-235
  • Q-301
  • Qi-507
  • roflumilast
  • RTU-1096
  • RVT-501
  • S-414114
  • SB-011
  • SB-414
  • SIG-1311
  • SIG-1322
  • 異位性皮膚炎用 S1PR1調整藥
  • 異位性皮膚炎用小分子
  • SP-14019
  • SUN-0597
  • SWT-01113
  • SWT-05141
  • 免疫學、皮膚疾病、遺傳性疾病用激肽釋放酶抑制合成肽
  • tacrolimus
  • tezepelumab
  • tofacitinib
  • tralokinumab
  • ustekinumab
  • VTP-38543
  • WBI-1001
  • WOL-071007
  • XmAb-7195
  • YJC-10592
  • Zafi-1
  • ZPL-3893787
  • ZPL-5212372

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8341IDB

Summary

Global Markets Direct's, 'Atopic Dermatitis - Pipeline Review, H2 2016', provides an overview of the Atopic Dermatitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Atopic Dermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Dermatitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis
  • The report reviews pipeline therapeutics for Atopic Dermatitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Atopic Dermatitis therapeutics and enlists all their major and minor projects
  • The report assesses Atopic Dermatitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Atopic Dermatitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Atopic Dermatitis Overview
  • Therapeutics Development
    • Pipeline Products for Atopic Dermatitis - Overview
    • Pipeline Products for Atopic Dermatitis - Comparative Analysis
  • Atopic Dermatitis - Therapeutics under Development by Companies
  • Atopic Dermatitis - Therapeutics under Investigation by Universities/Institutes
  • Atopic Dermatitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Atopic Dermatitis - Products under Development by Companies
  • Atopic Dermatitis - Products under Investigation by Universities/Institutes
  • Atopic Dermatitis - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Accolade Pharmaceuticals, LLC
    • AlbireoPharma
    • Almirall, S.A.
    • Amgen Inc.
    • Amorepacific Corporation
    • Anacor Pharmaceuticals, Inc.
    • AnaMar AB
    • AnaptysBio, Inc.
    • AnGes MG, Inc.
    • arGEN-X BV
    • Avexxin AS
    • Blueberry Therapeutics Ltd
    • Brickell Biotech, Inc.
    • Celgene Corporation
    • Cell Medica Limited
    • Cellceutix Corporation
    • ChemoCentryx, Inc.
    • ChironWells GmbH
    • Chugai Pharmaceutical Co., Ltd.
    • Creabilis SA
    • Curapel Limited
    • Dermala Inc
    • Dr. August Wolff GmbH & Co. KG Arzneimittle
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Foamix Pharmaceuticals Ltd.
    • Fountain Biopharma Inc.
    • Galapagos NV
    • GlaxoSmithKline Plc
    • Glenmark Pharmaceuticals Ltd.
    • Grupo Ferrer Internacional, S.A.
    • Han Wha Pharma Co., Ltd.
    • HanAll Biopharma Co., Ltd.
    • Heptares Therapeutics Limited
    • Herantis Pharma Plc
    • iCo Therapeutics Inc.
    • Immune Pharmaceuticals Inc.
    • Inflamalps SA
    • Japan Tobacco Inc.
    • Johnson & Johnson
    • Kang Stem Biotech Co., Ltd.
    • KPI Therapeutics, Inc.
    • LegoChem Biosciences, Inc
    • LEO Pharma A/S
    • Madam Therapeutics B.V.
    • MedImmune, LLC
    • NeoPharm Co., Ltd.
    • Nippon Shinyaku Co., Ltd.
    • Novan, Inc.
    • Novartis AG
    • Orbis Biosciences Inc
    • Otsuka Holdings Co., Ltd.
    • Oxagen Limited
    • Pfizer Inc.
    • Pharis Biotec GmbH
    • Pharmedartis GmbH
    • Provectus Biopharmaceuticals, Inc.
    • PuriCore Plc
    • Quorum Innovations LLC
    • Regeneron Pharmaceuticals Inc
    • Signum Dermalogix, Inc
    • Spherium Biomed S.L.
    • sterna biologicals Gmbh & Co KG
    • Sucampo Pharmaceuticals, Inc.
    • Sun Pharma Advanced Research Company Ltd.
    • SWITCH Biotech LLC
    • Takeda Pharmaceutical Company Limited
    • Thesan Pharmaceuticals, Inc.
    • Tioga Pharmaceuticals, Inc.
    • Torrent Pharmaceuticals Limited
    • Valeant Pharmaceuticals International, Inc.
    • Vicore Pharma AB
    • Vitae Pharmaceuticals, Inc.
    • VivaCell Biotechnology Espana S.L.
    • Xencor, Inc.
    • Ziarco Pharma Ltd
  • Atopic Dermatitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • A-3914 - Drug Profile
    • A-5425 - Drug Profile
    • AKP-11 - Drug Profile
    • Allergen for House Dust Mite Induced Atopic Dermatitis - Drug Profile
    • ALX-101 - Drug Profile
    • AM-1030 - Drug Profile
    • AMG-0101 - Drug Profile
    • Anatabine - Drug Profile
    • ANB-020 - Drug Profile
    • apremilast - Drug Profile
    • Aptamers to Inhibit Galectin-3 for Atopic Dermatitis - Drug Profile
    • ARGX-112 - Drug Profile
    • ARN-077 - Drug Profile
    • asimadoline - Drug Profile
    • AVX-001 - Drug Profile
    • B-244 - Drug Profile
    • baricitinib - Drug Profile
    • BB-2702 - Drug Profile
    • BBI-2000 - Drug Profile
    • BBI-5000 - Drug Profile
    • bertilimumab - Drug Profile
    • betamethasone valerate - Drug Profile
    • Biologic for Atopic Dermatitis and Eczema - Drug Profile
    • brilacidin tetrahydrochloride - Drug Profile
    • BTX-1204 - Drug Profile
    • C-21 - Drug Profile
    • CBP-174 - Drug Profile
    • CBP-201 - Drug Profile
    • CCX-6239 - Drug Profile
    • CDE-001 - Drug Profile
    • Cis-Urocanic Acid - Drug Profile
    • cobamamide - Drug Profile
    • crisaborole - Drug Profile
    • CT-101 - Drug Profile
    • CT-103 - Drug Profile
    • CT-327 - Drug Profile
    • CT-340 - Drug Profile
    • cyclosporine - Drug Profile
    • dalazatide - Drug Profile
    • DMT-210 - Drug Profile
    • Drug for Atopic Dermatitis - Drug Profile
    • dupilumab - Drug Profile
    • FB-825 - Drug Profile
    • fevipiprant - Drug Profile
    • FIB-116 - Drug Profile
    • Furestem-AD - Drug Profile
    • GBR-830 - Drug Profile
    • GLPG-2534 - Drug Profile
    • GSK-3772847A - Drug Profile
    • Histimex - Drug Profile
    • HS-378 - Drug Profile
    • IDP-124 - Drug Profile
    • JTE-052 - Drug Profile
    • KPI-150 - Drug Profile
    • LCB-030110 - Drug Profile
    • lebrikizumab - Drug Profile
    • LEKTI-6 - Drug Profile
    • LEO-32731 - Drug Profile
    • LEO-39652 - Drug Profile
    • MEDI-9314 - Drug Profile
    • mepolizumab - Drug Profile
    • MLR-1130 - Drug Profile
    • mometasone furoate - Drug Profile
    • Monoclonal Antibody to Antagonize PAR-2 for Atopic Dermatitis and Inflammation - Drug Profile
    • Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile
    • Monoclonal Antibody to Target Th22 cell/IL-22 pathway for Inflammatory Bowel Diseases, Atopic Dermatitis and Colorectal Cancer - Drug Profile
    • N-oleoylethanolamine - Drug Profile
    • nemolizumab - Drug Profile
    • NPH-12 - Drug Profile
    • NS-141 - Drug Profile
    • OC-000459 - Drug Profile
    • OC-2417 - Drug Profile
    • octenidine hydrochloride - Drug Profile
    • OLX-103 - Drug Profile
    • omiganan pentahydrochloride - Drug Profile
    • OPA-15406 - Drug Profile
    • P-10 - Drug Profile
    • P-148 - Drug Profile
    • PAC-14028 - Drug Profile
    • Peptide to Antagonize CX3CR1 for Atopic Dermatitis - Drug Profile
    • Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
    • PF-04965842 - Drug Profile
    • PH-10 - Drug Profile
    • PL-601 - Drug Profile
    • PMA-101R - Drug Profile
    • PMA-201 - Drug Profile
    • PMA-411R - Drug Profile
    • PR-022 - Drug Profile
    • prednisone - Drug Profile
    • PZ-235 - Drug Profile
    • Q-301 - Drug Profile
    • Qi-507 - Drug Profile
    • roflumilast - Drug Profile
    • RTU-1096 - Drug Profile
    • RVT-501 - Drug Profile
    • SB-011 - Drug Profile
    • SB-414 - Drug Profile
    • secukinumab - Drug Profile
    • SIG-1311 - Drug Profile
    • SIG-1322 - Drug Profile
    • Small Molecule for Atopic Dermatitis - Drug Profile
    • Small Molecule to Modulate S1PR1 for Atopic Dermatitis - Drug Profile
    • Small Molecules for Atopic Dermatitis - Drug Profile
    • Small Molecules for Atopic Dermatitis - Drug Profile
    • Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
    • SP-14019 - Drug Profile
    • SUN-0597 - Drug Profile
    • SWT-01113 - Drug Profile
    • SWT-05141 - Drug Profile
    • Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
    • tacrolimus - Drug Profile
    • tezepelumab - Drug Profile
    • tralokinumab - Drug Profile
    • upadacitinib tartrate - Drug Profile
    • ustekinumab - Drug Profile
    • VTP-38543 - Drug Profile
    • WBI-1001 - Drug Profile
    • WOL-071007 - Drug Profile
    • XmAb-7195 - Drug Profile
    • YJC-10592 - Drug Profile
    • Zafi-1 - Drug Profile
    • ZPL-389 - Drug Profile
    • ZPL-521 - Drug Profile
  • Atopic Dermatitis - Dormant Projects
  • Atopic Dermatitis - Discontinued Products
  • Atopic Dermatitis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Atopic Dermatitis, H2 2016
  • Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Atopic Dermatitis - Pipeline by AbbVie Inc, H2 2016
  • Atopic Dermatitis - Pipeline by Accolade Pharmaceuticals, LLC, H2 2016
  • Atopic Dermatitis - Pipeline by AlbireoPharma, H2 2016
  • Atopic Dermatitis - Pipeline by Almirall, S.A., H2 2016
  • Atopic Dermatitis - Pipeline by Amgen Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Amorepacific Corporation, H2 2016
  • Atopic Dermatitis - Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by AnaMar AB, H2 2016
  • Atopic Dermatitis - Pipeline by AnaptysBio, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by AnGes MG, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by arGEN-X BV, H2 2016
  • Atopic Dermatitis - Pipeline by Avexxin AS, H2 2016
  • Atopic Dermatitis - Pipeline by Blueberry Therapeutics Ltd, H2 2016
  • Atopic Dermatitis - Pipeline by Brickell Biotech, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Celgene Corporation, H2 2016
  • Atopic Dermatitis - Pipeline by Cell Medica Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Cellceutix Corporation, H2 2016
  • Atopic Dermatitis - Pipeline by ChemoCentryx, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by ChironWells GmbH, H2 2016
  • Atopic Dermatitis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Creabilis SA, H2 2016
  • Atopic Dermatitis - Pipeline by Curapel Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Dermala Inc, H2 2016
  • Atopic Dermatitis - Pipeline by Dr. August Wolff GmbH & Co. KG Arzneimittle, H2 2016
  • Atopic Dermatitis - Pipeline by Eli Lilly and Company, H2 2016
  • Atopic Dermatitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Fountain Biopharma Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Galapagos NV, H2 2016
  • Atopic Dermatitis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Atopic Dermatitis - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Atopic Dermatitis - Pipeline by Han Wha Pharma Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Herantis Pharma Plc, H2 2016
  • Atopic Dermatitis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Immune Pharmaceuticals Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Inflamalps SA, H2 2016
  • Atopic Dermatitis - Pipeline by Japan Tobacco Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Johnson & Johnson, H2 2016
  • Atopic Dermatitis - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by LegoChem Biosciences, Inc, H2 2016
  • Atopic Dermatitis - Pipeline by LEO Pharma A/S, H2 2016
  • Atopic Dermatitis - Pipeline by Madam Therapeutics B.V., H2 2016
  • Atopic Dermatitis - Pipeline by MedImmune, LLC, H2 2016
  • Atopic Dermatitis - Pipeline by NeoPharm Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Novan, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Novartis AG, H2 2016
  • Atopic Dermatitis - Pipeline by Orbis Biosciences Inc, H2 2016
  • Atopic Dermatitis - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by Oxagen Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Pfizer Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Pharis Biotec GmbH, H2 2016
  • Atopic Dermatitis - Pipeline by Pharmedartis GmbH, H2 2016
  • Atopic Dermatitis - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by PuriCore Plc, H2 2016
  • Atopic Dermatitis - Pipeline by Quorum Innovations LLC, H2 2016
  • Atopic Dermatitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Atopic Dermatitis - Pipeline by Signum Dermalogix, Inc, H2 2016
  • Atopic Dermatitis - Pipeline by Spherium Biomed S.L., H2 2016
  • Atopic Dermatitis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2016
  • Atopic Dermatitis - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
  • Atopic Dermatitis - Pipeline by SWITCH Biotech LLC, H2 2016
  • Atopic Dermatitis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Thesan Pharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Tioga Pharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Torrent Pharmaceuticals Limited, H2 2016
  • Atopic Dermatitis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Vicore Pharma AB, H2 2016
  • Atopic Dermatitis - Pipeline by Vitae Pharmaceuticals, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by VivaCell Biotechnology Espana S.L., H2 2016
  • Atopic Dermatitis - Pipeline by Xencor, Inc., H2 2016
  • Atopic Dermatitis - Pipeline by Ziarco Pharma Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Atopic Dermatitis - Dormant Projects, H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..1), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..2), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..3), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..4), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..5), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..6), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..7), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..8), H2 2016
  • Atopic Dermatitis - Dormant Projects (Contd..9), H2 2016
  • Atopic Dermatitis - Discontinued Products, H2 2016
  • Atopic Dermatitis - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Atopic Dermatitis, H2 2016
  • Number of Products under Development for Atopic Dermatitis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top